Skip to main content
. Author manuscript; available in PMC: 2016 May 12.
Published in final edited form as: Leukemia. 2014 Dec 23;29(6):1390–1401. doi: 10.1038/leu.2014.347

Figure 7. Single therapy with anti-ALK inhibitor leads to a partial response of ALCL1-11-PDT mice.

Figure 7

(A) ALCL-11 PDT2-6 (injected with 1×106 lymphoma cells, i.v) were analyzed using a dedicated MRI unit to determine the volume of the spleen as a surrogate of lymphoma/leukemia burden. Mice were treated with CEP28122, 100mg/kg/BID starting day 21th from the i.v. inoculum and scanned a different intervals (7, 14 or 21 days). A cohort of treated mice (14 days) were then released and followed overtime (7 or 14 days off). Numbers of mice are indicated.

(B) ALCL-11 PDT2-6 (injected with 1×106 lymphoma cells, i.v) were bled and blood circulating human CD45+CD30+ cells were determined by flow cytometry. Mice were treated with CEP28122, 100mg/kg/BID as indicate above. Numbers of mice are indicated.

(C) Effect of CEP28122 treatment in ALCL-11 PDT. Waterfall plot of mice injected with 1×106 ALCL-11 cells (i.v. day 21, grey bars) and CEP28122 response (day 21+14, back bars) after two weeks of treatment, compared with tumor volume at baseline (day 21), in 24 cases.

(D) Overall survival of ALCL-11-PDT treated with anti-ALK (CEP28122). Mice were randomized and treated as indicated with 100mg/kg/BID CEP28122 as indicated.